Dynavax Technologies Corporation (DVAX) Upgraded to “Outperform” by Royal Bank Of Canada

Royal Bank Of Canada upgraded shares of Dynavax Technologies Corporation (NASDAQ:DVAX) from a sector perform rating to an outperform rating in a research note issued to investors on Monday, July 31st, MarketBeat reports. They currently have $26.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $7.00.

DVAX has been the topic of a number of other reports. Zacks Investment Research cut Dynavax Technologies Corporation from a buy rating to a hold rating in a research note on Tuesday, July 11th. ValuEngine cut Dynavax Technologies Corporation from a sell rating to a strong sell rating in a research note on Friday, June 2nd. William Blair reiterated an outperform rating on shares of Dynavax Technologies Corporation in a research note on Thursday, July 27th. Finally, Cowen and Company reiterated an outperform rating and issued a $45.00 target price on shares of Dynavax Technologies Corporation in a research note on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. Dynavax Technologies Corporation currently has an average rating of Hold and an average price target of $23.34.

Dynavax Technologies Corporation (NASDAQ:DVAX) opened at 16.20 on Monday. Dynavax Technologies Corporation has a 52 week low of $3.20 and a 52 week high of $19.60. The firm has a 50-day moving average of $12.61 and a 200 day moving average of $7.57. The firm’s market capitalization is $886.90 million.

Dynavax Technologies Corporation (NASDAQ:DVAX) last announced its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.50) by $0.09. The firm had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.15 million. Dynavax Technologies Corporation had a negative return on equity of 92.09% and a negative net margin of 1,323.99%. During the same period last year, the business posted ($0.75) earnings per share. Analysts predict that Dynavax Technologies Corporation will post ($1.58) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Dynavax Technologies Corporation (DVAX) Upgraded to “Outperform” by Royal Bank Of Canada” was originally reported by BNB Daily and is the sole property of of BNB Daily. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.baseball-news-blog.com/2017/08/19/dynavax-technologies-corporation-dvax-upgraded-to-outperform-by-royal-bank-of-canada-updated-updated.html.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC raised its position in shares of Dynavax Technologies Corporation by 54.5% in the second quarter. Cubist Systematic Strategies LLC now owns 10,493 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 3,700 shares during the period. Patriot Financial Group Insurance Agency LLC raised its position in shares of Dynavax Technologies Corporation by 16.5% in the second quarter. Patriot Financial Group Insurance Agency LLC now owns 12,000 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 1,700 shares during the period. DekaBank Deutsche Girozentrale acquired a new position in shares of Dynavax Technologies Corporation during the first quarter worth approximately $121,000. Bank of America Corp DE raised its position in shares of Dynavax Technologies Corporation by 2.3% in the first quarter. Bank of America Corp DE now owns 20,356 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 456 shares during the period. Finally, Legal & General Group Plc raised its position in shares of Dynavax Technologies Corporation by 18.5% in the second quarter. Legal & General Group Plc now owns 12,501 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 1,950 shares during the period. 57.49% of the stock is currently owned by institutional investors.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply